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Steatosis
Fibrosis
> 450 patients with 
suspicion of NAFLD 
prospectively recruited
>Underwent liver biopsy within 2 
weeks of FibroScan 
(M or XL probe according to the 
automatic probe recommendation tool)
>Results and conclusions
CAP (dB/m)
LSM (kPa)
CAP for steatosis (S≥1):
> AUC = 0.87 (0.82-0.92)
LSM for advanced fibrosis (F≥3): 
> AUC = 0.80 (0.75-0.84)
LSM for cirrhosis (F=4):
> AUC = 0.89 (0.84-0.93)
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Specificity
> Steatosis or probe type had no impact on LSM (multivariable analysis)
>>> CAP and LSM by FibroScan are reliable
biomarkers to  non-invasively assess liver
steatosis and fibrosis respectively in NAFLD
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Abstract 
Background & Aims: We estimated the accuracy of FibroScan vibration-controlled transient 
elastography controlled attenuation parameter (CAP) and liver stiffness measurements 
(LSMs) in assessing steatosis and fibrosis in patients with suspected NAFLD. 
 
Methods: We collected data from 450 consecutive adults who underwent liver biopsy 
analysis for suspected NAFLD at 7 centers in the United Kingdom from March 2014 through 
January 2017. FibroScan examinations with M or XL probe were completed within the 2 
weeks of the biopsy analysis (404 had a valid examination). The biopsies were scored by 2 
blinded expert pathologists according to non-alcoholic steatohepatitis clinical research 
network criteria. Diagnostic accuracy was estimated using the area under the receiver 
operating characteristic curves (AUROC) for the categories of steatosis and fibrosis. We 
assessed effects of disease prevalence on positive and negative predictive values. For LSMs, 
the effects of histological parameters and probe type were appraised using multivariable 
analysis. 
 
Results: Using biopsy analysis as the reference standard, we found that CAP identified 
patients with steatosis with an AUROCs of 0.87 (95% CI, 0.82–0.92) for S≥S1, 0.77 (95% 
CI, 0.71–0.82) for S≥S2, and 0.70 (95% CI, 0.64–0.75) for S=S3. Youden cut-off values for 
S≥S1, S≥S2 and S≥S3 were 302 dB/m, 331 dB/m, and 337 dB/m respectively. LSM 
identified patients with fibrosis with AUROCs of 0.77 (95% CI, 0.72–0.82) for F≥F2, 0.80 
(95% CI, 0.75–0.84) for F≥F3, and 0.89 (95% CI, 0.84–0.93) for F=F4. Youden cut-off 
values for F≥F2, F≥F3 and F=F4 were 8.2 kPa, 9.7 kPa, and 13.6 kPa respectively. Applying 
the optimal cut-off values, determined from this cohort, to populations of lower fibrosis 
prevalence increased negative predictive values and reduced positive predictive values. 
Multivariable analysis found that the only parameter that significantly affect LSMs was 
fibrosis stage (P<10-16); we found no association with steatosis or probe type. 
 
Conclusions: In a prospective analysis of patients with NAFLD, we found CAP and LSMs 
by FibroScan to assess liver steatosis and fibrosis, respectively, with AUROC values ranging 
from 0.7 to 0.89. Probe type and steatosis did not affect LSMs. Study registration: 
ClinicalTrials.gov Identifier: NCT01985009. 
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KEY WORDS:  VCTE, NASH, non-invasive, biomarker 
Background & Aims:  
Non-alcoholic fatty liver disease is an increasingly common cause of chronic liver disease, 
and is expected to soon become the commonest indication for liver transplantation1, 2. 
Estimates of its prevalence vary from 20-40% in the general population, although only 1-3% 
have evidence of significant inflammation and fibrosis3. The presence of liver fibrosis in 
particular is an important predictor of clinical events, both in terms of overall mortality and 
also liver-related morbidities and mortality4, 5. The challenge therefore remains how to 
identify those individuals with NAFLD that have more significant pathology in a manner 
which is non-invasive and affordable by healthcare systems. 
 
Vibration-controlled transient elastography (VTCE) is one such approach which is in 
widespread clinical usage and for which there is an increasing understanding of clinically 
relevant cut-off values. By the use of a pulse-echo ultrasonic acquisition, vibration-controlled 
transient elastography (VCTE) can quantify the speed of a mechanically induced shear wave 
in liver tissue and hence generate an estimate of the degree of liver fibrosis with a liver 
stiffness measurement (LSM)6, 7. More recently this has been supplemented by the ability to 
quantify hepatic steatosis by measuring ultrasonic attenuation of the echo wave, termed the 
controlled attenuation parameter (CAP)8, 9, which has been compared to liver biopsy in 
prospective studies with the M probe10-12.  
 
Previous studies have demonstrated the limitations of the M probe in patients with an 
increased skin to liver capsular distance as can occur commonly in NAFLD and 
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overweight/obese patients13, 14; there is a much higher failure rate which led to the 
development of the XL probe. However, much of the published literature with the XL probe 
and CAP consists of either retrospective15 or small/medium prospective cohort studies16-19, 
with the exception of the recent NASH CRN studies20, 21. However, none have been the 
subject of large prospective powered diagnostic studies adhering to standards for reporting of 
diagnostic accuracy studies (STARD) guidelines22.  
 
Importantly, there are still uncertainties about the impact of other histological features on 
LSM readings with reports suggesting that steatosis may be a contributor23, 24, although these 
studies were limited in that only the M probe was used. Similarly, whilst the advent of the XL 
probe has markedly reduced the failure rate in overweight/obese individuals25, there are 
reports suggesting that cut-off ranges differ according to probe choice26. 
 
We designed a large prospective diagnostic study across 7 centres in the United Kingdom to 
evaluate the diagnostic accuracy of CAP measured either with the M or XL probe (depending 
on the FibroScan device automatic probe recommendation tool) in patients being investigated 
for potential NAFLD compared to a reference standard of histological evaluation of steatosis. 
The secondary objectives were to evaluate the diagnostic accuracy of LSM (with either M or 
XL probe) compared to a reference standard based on histological evaluation of fibrosis, and 
study of impact of histological parameters and probe type on LSM reading. In addition we 
aimed to identify cutoffs for use in clinical practice with both CAP and LSM.  
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Methods 
Study participant and design 
The study was a cross-sectional prospective multi-centre study, with the primary and 
secondary outcomes being to assess the diagnostic accuracy of CAP and LSM against liver 
histology which is the gold standard to evaluate the liver steatosis and fibrosis. NAFLD was 
suspected on the basis of the presence of abnormal liver enzymes in the presence of an 
ultrasound scan showing and echobright liver was the principle reason, usually in the 
presence of metabolic syndrome components. The STARD guidelines were followed to 
report the methods and results of this study22 (see Supplementary Table 1 for further details). 
Consecutive patients were prospectively recruited between March 2014 and January 2017 in 
7 liver centres across the United Kingdom (University Hospitals Birmingham NHS 
Foundation Trust, Birmingham; Addenbrooke’s Hospital, Cambridge; Royal Free Hospital, 
London; Freeman Hospital, Newcastle upon Tyne; University Hospitals Plymouth NHS 
Trust, Plymouth; Queen’s Medical Centre, Nottingham and John Radcliffe Hospital, Oxford). 
 
The study (NCT01985009) was approved by the North Wales Research Ethics Committee 
(13/WA/0385) and by the Local Research Ethics Committee at each centre. All patients gave 
written informed consent to participate in the study. The study was conducted in accordance 
with the declaration of Helsinki and in agreement with the International Conference on 
Harmonisation (ICH) guidelines on Good Clinical Practice (GCP). All authors had access to 
the study data and reviewed and approved the final manuscript. 
 
Main analyses: The primary outcome of the protocol was to evaluate the diagnostic accuracy 
of CAP measured either with the M or XL probe (depending on the FibroScan device 
automatic probe recommendation tool) against histological evaluation of steatosis. A 
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secondary outcome of the protocol was to evaluate the diagnostic accuracy of liver stiffness 
measured either with M or XL probe (depending on the FibroScan device automatic probe 
recommendation tool) against histological evaluation of fibrosis. 
  
Inclusion and exclusion criteria 
Inclusion criteria were as follows: patients were ≥18 years of age, able to give written 
informed consent and were scheduled, independently from this study, to have a liver biopsy 
(LB) for investigation of assumed NAFLD within 2 weeks of Fibroscan examination (before 
or after). Patients were also negative for HBsAg, anti-HCV, HCV-RNA and HBVDNA. 
Exclusion criteria were as follows: patients with ascites, pregnant women, patient with any 
active implantable medical device (such as pacemaker or defibrillator), patients who had 
undergone liver transplantation, patients with cardiac failure and/or significant valvular 
disease, patients with haemochromatosis, patients that refused to undergo liver biopsy or 
blood tests, patients with an alcohol consumption above recommended limits (>14 units/week 
for women and >21 units/week for men; 1 unit = 8 g of ethanol), patients with a confirmed 
diagnosis of active malignancy, or other terminal disease, patient participating in another 
clinical trial within the preceding 30 days. 
 
Patient Characteristics 
The following characteristics were recorded for each patient: age, gender, BMI, presence of 
diabetes, hypertension, and hypercholesterolemia. For each patient, a 12 hour fasting blood 
collection was performed locally on the same day of the FibroScan procedure and was then 
shipped to a central laboratory for assessment of the following laboratory parameters: 
platelets count, international normalized ratio (INR), aspartate transaminase (AST), alanine 
transaminase (ALT), gamma-glutamyl-transferase (GGT), alkaline phosphatase, albumin, 
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bilirubin, fasting glucose, total cholesterol, high density lipoprotein (HDL) cholesterol, low 
density lipoprotein (LDL) cholesterol, triglyceride, ferritin, urea, creatinine, alpha-2-
macroglobulin (A2M), hyaluronic acid, C-reactive protein (CRP) and cytokeratin 18 neo-
epitope M30 (CK18-M30). 
 
Histopathologic evaluation 
Percutaneous LB was performed on all patients according to local standard procedure LB 
specimens were fixed in formalin, embedded in paraffin and stained with Hematoxylin and 
Eosin and Sirius Red for fibrosis evaluation. Slides were analysed independently by two 
experienced pathologists (PB and VP) who were blinded to each other’s reading and also to 
the patient’s clinical and Fibroscan data if available. In case of disagreement, they reviewed 
the slides together to reach consensus. 
 
Steatosis (from 0 to 3), ballooning (from 0 to 2), lobular inflammation (from 0 to 3), fibrosis 
(from 0 to 4) and NAFLD activity score (NAS) were scored using the NASH clinical 
research network (NASH CRN) scoring system 27. NASH was diagnosed using the “fatty 
liver: inhibition of progression” (FLIP) definition (presence of steatosis, hepatocyte 
ballooning and lobular inflammation with at least 1 point for each category). In addition, 
steatosis was semi-quantitatively assessed in percentage and the activity score (Ballooning 
(0-2) plus lobular inflammation (0-2)) according to the Steatosis Activity Fibrosis (SAF) was 
also assessed 28. The presence of portal inflammation was also recorded. Biopsies were 
categorised by the pathologists as normal liver (no liver pathology), NAFL (steatosis but no 
NASH), NASH or other diagnosis when no NAFLD but other histological features suggestive 
of another diagnostic were observed (e.g. granulomatous hepatitis, biliary disease, 
autoimmune hepatitis). Interpretability for liver biopsy was based on the standard criteria of 
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length, width and lack of major fragmentation. These criteria were occasionally over-looked 
by the pathologist when the biopsy showed obvious histological criteria of NASH, septal 
fibrosis or cirrhosis even if the biopsy was small or fragmented. 
 
FibroScan liver stiffness measurement and controlled attenuation parameter 
FibroScan (Echosens, Paris, France) examination was performed in each centre by nurses or 
physicians trained and certified by the manufacturer and blinded to the patient’s histological 
evaluation. The FibroScan used in each center was a FibroScan 502 Touch model, equipped 
with both M and XL probes. An automatic probe selection tool was embedded in the device 
software which recommends the appropriate probe for each patient according to the real time 
assessment of the skin to liver capsule distance. The FibroScan examination procedure has 
been detailed previously6, 29. Briefly, all patients were asked to fast at least 3 hours prior to 
the examination, and then placed in the supine position with their right arm fully abducted. 
Measurements were performed by scanning the right liver lobe through an intercostal space.  
 
The FibroScan device simultaneously measures LSM and CAP using VCTE technology. 
CAP has been designed to measure liver ultrasonic attenuation (go and return path) at 3.5 
MHz on both M and XL probes8, on signals acquired by the Fibroscan. The principle of CAP 
measurement has been described elsewhere8, 9, and CAP was computed only when the 
associated LSM was valid and using the same signals as the one used to measure liver 
stiffness. At the beginning of the study, CAP was not available on the XL probe, therefore, 
the raw ultrasonic radio-frequency signals were stored in the Fibroscan examination file to 
enable computation of CAP off-line. CAP computation was performed blinded to all patients’ 
clinical and histological data using the exact same configuration and algorithm to the one 
embedded in the commercial device for N=116 patients. When CAP was commercially 
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available for the XL probe, all software were updated and the CAP value was displayed on 
the device screen for both probes during the procedure. The final CAP and LSM results were 
expressed in dB/m and kPa respectively. Only examinations with at least 10 valid individual 
measurements were deemed valid. 
 
Statistical Analysis 
Sample size estimation: Since no study had been performed previously using the probe 
recommendation on the FibroScan device, the sample size was calculated for patient 
measured with the XL probe only. It was hypothesized that approximately 1/3 of the total 
patients would be measured with M probe. Given the expected performance of CAP to detect 
steatosis (S≥S1) with an AUROC≥0.809, 30, 31, a projected sample size of 212 patients was 
deemed necessary to estimate an AUROC of 0.80 with the XL probe with an (1-α) 
confidence interval, α being set to 5%, at a 5% standard error level, for the XL probe only. 
The total number of patients measured using both probes was set to 312 patients and the final 
number of patients was set at 450 assuming a 30% drop-out rate   
 
For descriptive statistics, continuous variables were expressed as medians [interquartile range 
(IQR)] and categorical variables as absolute figures with percentages. Confidence intervals 
were reported at the 95% level. Evidence for differences between CAP and LSM between 
steatosis grades and fibrosis stages was assessed using Kruskal-Wallis test followed by 
Dunn's tests with post hoc comparison. P values of < 0.05 were considered statistically 
significant. 
 
Overall diagnostic accuracy of CAP and LSM was estimated as the area under the ROC curve 
(AUROC) together with its 95% confidence interval (CI). Data are reported for thresholds of 
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steatosis and fibrosis. Cut-off values for CAP and LSM were identified that (a) maximise the 
Youden index, and also (b) at fixed values of sensitivity and specificity of 90%. For each cut-
off value, we reported sensitivity (Se), specificity (Sp), positive predictive value (PPV), 
negative predictive value (NPV), positive likelihood ratio (LR+), negative likelihood ratio 
(LR-) together with 95% confidence intervals. In additional analyses we investigated the 
performance of the tests in settings with different prevalence using Bayes equation to 
estimate post-test probabilities from the estimated likelihood ratios. For these computations 
we focused on fibrosis thresholds of F≥F2 and F=4 which are of particular importance as they 
correspond with stages which result in changes in patient management. We also identified 
cutoffs which minimized the consequences of test errors across different relative weightings 
of false positives and false negatives (see Supplementary Methods). 
 
Factors influencing LSM: To evaluate the impact of histological parameters that possibly 
influenced LSM, a multivariable linear regression model was constructed with fibrosis stage, 
steatosis grade, ballooning grade, lobular inflammation and portal inflammation as candidate 
covariates and LSM as the outcome variable. In addition, the probe type used (M or XL) was 
also entered as a candidate covariate to evaluate if it had an impact on LSM when adjusted on 
histological parameters. All first order interactions were entered into the model. LSM was 
Box-Cox transformed to approximate a normal distribution. Final model selection was 
performed with a backward elimination procedure based on Bayesian information criteria 
(BIC). Multi-collinearity of independent variables was checked using the variance inflation 
factor.  In addition to this multivariable analysis, LSM versus fibrosis stage stratified by 
probe type and by semi-quantitative steatosis percentage quartile was represented using a 
boxplot. Univariate analysis was performed using Kendall rank correlation coefficient 
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between each histological parameter and LSM and was performed using the Mann-Whitney 
U test between the probe type and LSM. 
 
The sensitivity analyses on CAP and LSM diagnostic accuracy and the analyses relative to 
the influence of disease prevalence on PPV and NPV, the cutoffs which minimized the 
consequences of test errors across different relative weightings of false positives and false 
negatives and factors influencing LSM were exploratory analyses which were not pre-
specified.  
 
For all analyses, only patients with histological results and median LSM or CAP values 
available with at least ten valid measurements were analyzed. In addition, no replacement of 
missing data has been performed. All analyses were performed using the software R, version 
3.3.032. 
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Results 
Patient Characteristics 
The study flow chart is represented in Figure 1. Table 1 details the clinical, serological, 
histological characteristics and Fibroscan data of 383 patients with a valid FibroScan reading 
and an interpretable liver biopsy.  
 
FibroScan applicability  
Of 415 patients evaluated using the FibroScan (Figure 1), 138 (33%) were with the M probe 
and 277 (67%) with the XL probe. FibroScan readings were valid (with at least 10 valid 
individual measurements as per the manufacturer's recommendations) in 404 patients leading 
to an applicability value of 97%. For the 11 patients for whom a valid FibroScan was not 
achieved; 2 were with the M probe and 9 with the XL probe. Of note 4 of these 11 patients 
had 9 valid measurements (rather than the 10 required). Patients with less than 9 valid 
measurements (n=7) had a significantly higher BMI than others (46.5 [13.6] kg.m-2 versus 
36.4 [9.2] kg.m-2; P = 0.003). Within the 404 patients with valid FibroScan, patients assessed 
with the XL probe (N=268) had a significantly higher BMI than patients measured by the M 
probe (36.3 [7.8] kg.m-2 versus 29.3 [4.7] kg.m-2; P < 10-16). No adverse event has been 
reported related to the use of the FibroScan device. 
 
Liver biopsies 
A total of 412 patients underwent LB (see Figure 1: 433 eligible patients minus 16 patients 
who did not have LB, 4 patients who had LB cancelled by the investigator and 1 patient who 
withdrew consent before LB). The LB slides of 3 patients were lost during shipment and a 
further 15 LB were judged as non-interpretable by the pathologist leaving 394 (96%) as 
having an interpretable LB. A further ten patients had a LB that although interpretable by the 
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pathologist could not be staged according to the NASH CRN scoring system. A description 
of those LB is provided in Supplementary Table 2 (2 patients being NAFLD with associated 
lesions and 8 being not NAFLD but not normal liver). Of note, 33 patients (8% of the patients 
with interpretable LB) had a histological diagnosis other than NAFLD or normal liver. A 
description of those LB is provided in Supplementary Table 2. After LB, 3 adverse events 
were reported: 1 patient had a syncopal episode following LB and pain at LB site requiring 
oral analgesia, 1 patient had hemorrhage following LB requiring hospitalization and 1 patient 
was admitted with pain and fever.  
 
Assessment of steatosis using controlled attenuation parameter 
Of 415 patients, 380 patients had an interpretable liver biopsy and valid CAP values (Figure 
1). According to histological assessment, steatosis grade distribution was as follows: S0 = 47 
(12%), S1 = 89 (23%), S2 = 107 (28%), S3 = 137 (36%) and the boxplot of CAP versus 
steatosis grade is shown in Figure 2a. CAP was significantly different between S0, S1 and S2 
but not S2 and S3 (Kruskal-Wallis H = 97.70, P < 10-16; Dunn's post hoc tests, P = 0.19 
between CAP in S2 and CAP in S3, P < 10-3 otherwise). Areas under the ROC curve 
(AUROC) as well as diagnostic performance of CAP cut-off values optimized using 
Youden’s index, a sensitivity of 90% or a specificity of 90% are detailed in Table 2 for S0 
versus S1 and above, S0-S1 versus S2-S3 and S0-S2 versus S3. Accuracy was highest at the 
S≥S1 threshold, with an AUROC of 0.87 (95% CI: 0.82-0.92) and sensitivity of 0.80 (0.75-
0.84) and specificity of 0.83 (0.69-0.92) at a threshold of 302 dB/m selected by maximizing 
Youden’s Index. Accuracy dropped to an AUC of 0.77 (0.71-0.82) for the S≥S2 threshold, 
with the corresponding sensitivity of 0.70 (0.63-0.75) and specificity of 0.76 (0.68-0.83) at 
the threshold of 331 dB/m maximizing Youden’s index and to an AUROC of 0.70 (0.64-
0.75) for the S=S3 threshold with the corresponding sensitivity of 0.72 (0.63-0.79) and a 
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specificity of  0.63 (0.56-0.69) at the threshold of 337 dB/m maximizing Youden’s index. 
The ROC plots for S≥S1, S≥S2 and S=S3 are given in Supplementary Figure 1. Performance 
of CAP to diagnose NASH was also assessed. Corresponding AUC was 0.71 (0.65-0.76). 
 
The use of quality criteria based on the IQR of CAP as proposed by Caussy et al 33 and Wong 
et al 34 which recommend excluding patients with IQR of CAP greater or equal to 30 dB/m or 
40 dB/m, respectively was tested in our cohort. A large proportion of patients had an IQR of 
CAP ≥30 or 40 dB/m (57% and 39%, respectively), and performance was no better in 
patients with an IQR of CAP <30 or <40 dB/m (Supplementary Table 3). Indeed for the 
diagnosis of higher stages of steatosis performance was even lower in patient with an IQR of 
CAP <30 or <40 dB/m. To determine the influence of serum ALT on CAP diagnostic 
performance patients were stratified by ALT values (≤ULN, between ULN and 2xULN and 
>2xULN), but this did not influence CAP AUROCs (Supplementary Table 4). Performance 
of CAP was compared to the hepatic steatosis index (HSI) 35 in a subset of patients (N=375, 
due to 5 missing biological data). CAP significantly outperformed HSI for each steatosis 
grade S≥S1, S≥S2 and S=S3 (Supplementary Table 5). 
 
Assessment of fibrosis using liver stiffness measurement 
Of the 384 patients with valid LSM and interpretable LB, only 373 had fibrosis interpretable 
according to the NASH CRN scoring system (Figure 1). Differences in characteristics 
between the 373 patients used for fibrosis staging analysis and the 10 patients with fibrosis 
not staged are given in Supplementary Table 6. 
 
Fibrosis stage distribution was as follows: F0: 62 (17%), F1: 86 (23%), F2: 85 (23%), F3: 
106 (28%), F4: 34 (9%). LSM versus fibrosis stage is presented as a boxplot in Figure 2b. 
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LSM was significantly different between all fibrosis stages with the exception of F0 and F1 
(Kruskal-Wallis H = 119.8, P < 10-16; Dunn's post hoc tests, P = 1 between LSM in F0 and 
LSM in F1, P < 0.05 otherwise). AUC as well as diagnostic performance of LSM cut-off 
values optimized using Youden’s index, a sensitivity of 90% or a specificity of 90% are 
detailed in Table 3 for F0-F1 versus F2 and above, F0-F2 versus F3-F4 and F0-F3 versus F4. 
Accuracy was highest at the F=F4 threshold, with an AUC of 0.89 (95% CI: 0.84-0.93) and 
sensitivity of 0.85 (0.69-0.95) and specificity of 0.79 (0.74-0.83) at a threshold of 13.6 kPa 
selected by maximizing Youden’s Index. Accuracy was lower at lower fibrosis thresholds 
dropping to an AUROC of 0.80 (0.75-0.84) for F≥F3 with the corresponding sensitivity of 
0.71 (0.62-0.78) and a specificity of 0.75 (0.69-0.80) at a threshold of 9.7 kPa maximizing the 
Youden’s index and to an AUROC of 0.77 (0.72-0.82) for the F≥F2 threshold, with the 
corresponding sensitivity of 0.71 (0.64-0.77) and specificity of 0.70 (0.62-0.77) at the 
threshold of 8.2 kPa maximizing the Youden’s index. The ROC plots for F≥F2, F≥F3 and 
F=F4 are given in Supplementary Figure 2. Performance of LSM to diagnose NASH was also 
assessed. Corresponding AUC was 0.68 (0.62-0.74). 
 
The performance of the Boursier criteria36 as a quality control for Fibroscan were evaluated 
in this cohort (IQR/median<30% in patient with LSM≥7.1 kPa). Whilst 43 (12%) patients did 
not reach the Boursier criteria, analysis in this cohort did not find evidence that these criteria 
improved performance of Fibroscan (Supplementary Table 7) where we have assessed 
AUROC for patients reliable according to Boursier’s criteria only. The influence of ALT on 
LSM diagnostic performance was evaluated by stratifying patients on ALT values (≤ULN, 
between ULN and 2xULN and >2xULN). No significant influence of the effect of ALT on 
the LSM AUROC for each fibrosis stage was observed (Supplementary Table 8). The 
performance of the Baveno VI cut-offs37, in relation to patients with compensated advanced 
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chronic liver disease with advanced fibrosis (F≥F3) were tested in this cohort. The NPV 
associated with the ≤10 kPa cutoff was 0.80 and the PPV associated with the ≥15 kPa cutoff 
was 0.75. 
Performance of LSM was also compared to Fib438 and the NAFLD fibrosis score (NFS39). 
Diagnostic performance in terms of AUROC for each fibrosis stage (≥F2, F≥F3 and F=F4) 
are provided in Supplementary Table 9. LSM outperformed Fib4 and NFS for the diagnosis 
of cirrhosis and NFS for the diagnosis of F≥2. For the diagnosis of advanced fibrosis, 
performance of LSM was compared using the dual cut-offs (cut-off for Se≥0.90 = 7.1 kPa 
and cut-off for Sp≥0.90 = 14.1 kPa determined in the present cohort) against the dual cut-offs 
for Fib4 (1.30 and 3.25)38 and NFS (-1.455 and 0.676)39. LSM had a higher Se for the 
confirmation of advanced fibrosis (F≥3) with a PPV = 0.74 (Supplementary Table 10). 
  
Further analysis was performed to identify cutoffs which minimized the consequences of test 
errors across different relative weightings of false positives and false negatives (see 
Supplementary Results and Supplementary Table 11). In these analyses the consequences of 
diagnostic error were explored in situations where the priority was to either avoid false 
positive diagnoses (for the diagnostic of F≥F2) or false negative diagnoses (for the diagnostic 
of F=F4). The analyses were performed under a range of scenarios with the cost of a false 
positive (FP) being set at 2 times, 5 times and 10 times worse than a false negative (FN) for 
the diagnostic of F≥F2. The effect on threshold is shown in Supplementary Table 11 along 
with the corollary analyses for the diagnostic of F=F4.   
 
Impact of fibrosis prevalence on predictive value of liver stiffness measurement 
We set out to determine the impact of fibrosis prevalence on PPV and NPV values by 
utilising a range of different pre-test probabilities values (prevalence). The prevalence figures 
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used represent values from this cohort (60, 38% and 9% for F≥F2, F≥F3 and F=4 
respectively) and also values seen in cohorts of patients with type 2 diabetes mellitus, patients 
at risk of liver disease and the general population40-42. For a diagnosis of F≥F2, F≥F3 and 
F=F4 there was a marked reduction in the PPV as the prevalence of fibrosis was lowered 
(Table 4). Rounding the proposed cut-offs did not affect the PPV and NPV, irrespective of 
prevalence (see Supplementary Table 12). 
 
Influence of probe type and histological parameters on liver stiffness measurement 
We next investigated the influence of probe type and histological parameters on LSM values. 
In univariate analysis, no significant difference was found between LSM and the probe type 
(P = 0.55); all histological parameters were significantly correlated to LSM: fibrosis stage (τ 
= 0.43, P < 10-16), ballooning grade (τ = 0.22, P < 10-7), lobular inflammation grade (τ = 0.21, 
P < 10-6), portal inflammation grade (τ = 0.17, P < 10-4) and steatosis grade (τ = 0.11, P = 
0.004). Then, a multivariable linear regression analysis was performed. Following a 
backward selection procedure based on BIC, the only covariate influencing LSM was fibrosis 
stage (β = 0.18, 95% CI = (0.15-0.21), P < 10-16). When adjusted for fibrosis stage, there was 
no significant influence of probe type or steatosis grade on the LSM value. To further 
illustrate this, a boxplot of LSM versus fibrosis stage stratified by probe type is presented in 
Figure 3a and a boxplot of LSM stratified by semi-quantitative steatosis percentage quartile is 
presented in Figure 3b.  
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Conclusions 
This prospective study examined the association of contemporaneous VTCE and liver 
histology in a cohort of patients undergoing liver biopsy for investigation for suspected 
NAFLD, and the results were reported according to the STARD guidelines. It demonstrates 
the high applicability rate of VTCE (97%) in a large UK NAFLD cohort with BMI up to 53.2 
kg/m² and provides optimised cut-off values for staging steatosis and fibrosis depending on 
prevalence and clinical context (Youden criteria, 90% sensitivity or 90% specificity). This 
study also provides novel approaches to threshold setting taking into account the prevalence 
of fibrosis in the population to be tested and also basing thresholds around clinical priorities 
such as minimising false positive diagnoses of F≥F2 or false negative diagnoses of F=4. 
Critically this study demonstrates that only fibrosis stage, and not probe type or any other 
histological parameters, influence LSM values.  
 
Whilst the cut-offs for steatosis grade increase progressively from S0 to S3 when set for high 
sensitivity or high specificity there is not much difference between S2 and S3 when using the 
Youden cut-off values which were 331 dB/m and 337 dB/m respectively. Nevertheless in 
clinical practice the identification of moderate steatosis is of greater utility than distinctions 
between S2 and S3, and thus the Youden cut-off for S ≥S2 of 331 dB/m is sufficient. The 
determination of steatosis by CAP is relevant for the confirmation of any degree of steatosis 
and also potentially as a serial measure in response to lifestyle or pharmacological/surgical 
intervention. The former is demonstrably feasible in this study whereas the latter will require 
examination in intervention studies.  
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With regards to the association between LSM values and histological evaluation of liver 
fibrosis there is a clear demarcation between the different degrees of fibrosis for Youden cut-
off as well as for those with high sensitivity or specificity. As expected the cut-off for liver 
cirrhosis is markedly higher at 20.9 kPa when the specificity is set at 90%. The Youden cut-
off values from this study for F≥F2, F≥F3 and F=F4 were 8.2 kPa, 9.7 kPa, and 13.6 kPa 
respectively, which demonstrate a clear upward increment with progressive liver fibrosis. 
These cut-off values have good sensitivity and specificity with a good PPV (0.78) for ≥F2 
and an excellent NPV (0.98) for F4. Distinguishing F0-F2 versus F3-4 can be achieved 
despite a slightly lower PPV (0.63), although there is a higher NPV (0.81) with the cut-off for 
F≥F3. 
 
The diagnostic performance of LSM and cutoffs for stages of fibrosis in this study are 
broadly in keeping with data from a US cohort20 (Supplementary Table 13) and those 
recommended in a UK guideline43. The cutoffs from a range of other published studies are 
included in Supplementary Table 14 for comparison. Whilst reasonably similar there are 
some differences in the UK cohort such as gender (45% female vs 68% female in US cohort) 
and presence of diabetes mellitus (50% vs 44% in US cohort). For CAP however, diagnostic 
performance is higher in our cohort than in the US cohort (AUROC 0.87 (0.82-0.92) for the 
diagnostic of S≥1 in our cohort versus 0.76 (0.64-0.89) in the US cohort. This difference may 
be accounted to the prevalence of patients with S≥S1 steatosis which is 88% in our cohort 
versus 95% in the US cohort. Another possibility is that the delay between FibroScan and LB 
was up to 12 months in NASH CRN study whereas in this study it was only 2 weeks. 
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Reports have suggested that factors other than liver fibrosis, such as steatosis23, may 
influence LSM readings. To evaluate this question we performed multivariable analysis 
including all potentially relevant factors and notably the only factor that predicted LSM was 
the degree of liver fibrosis. Explicitly, neither the degree of steatosis or inflammation was 
associated with differences in LSM. This is likely because prior studies had not included 
other factors such as degree of fibrosis in their analyses, which when taken into account 
reveal that other histological elements do not influence LSM readings23. Also these studies 
only used the M probe which is likely to give an incorrect reading in many patients with 
NAFLD. Similarly, groups have suggested that LSM cut-offs differ according to probe 
choice20, 26, although in this study we did not find this to be the case.  
 
The threshold values will also be significantly impacted by the prevalence of the underlying 
condition. In Table 4 the effect of changing prevalence is demonstrated again allowing for 
appropriate choice of cut-off values depending on the clinical setting. This modelling data 
demonstrates that as the prevalence of liver fibrosis (≥F2 or F4) decreases there is a 
commensurate reduction in PPV and increase in NPV. This is relevant as cut-offs generated 
in secondary care are often applied in primary care without taking into account the marked 
difference in prevalence. In this situation a negative test would be very reassuring although a 
positive test would have a low likelihood of capturing a true positive and raises the question 
of needing further confirmatory tests. 
 
Conventional cut-off criteria for grades of steatosis and fibrosis whilst useful, do not capture 
the importance to clinical decision making and its dependence on the relevant clinical setting. 
To better model this we explored two settings; one in which the presence of ≥F2 or F4 was 
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being tested (Supplementary Appendix). In the former setting (≥F2) the assumption was 
made that a false positive was two, five or ten times worse than a false negative, with 
concomitant increases in the threshold. In contrast for F4 the opposite view was taken, 
namely that it was more important to not miss a diagnosis (Supplementary Table 11). This 
allows for healthcare organisations to make decision depending on how they value the ratio 
of false positive to false negatives. 
 
Our study has several strengths; it is a large prospective appropriately powered study, and 
captures real world clinical practice of clinicians evaluating patients with potential NAFLD. 
By incorporating the automatic probe recommendation tool we also ensured that the correct 
probe was used to generate LSM and CAP values. It defines a number of cut-offs which can 
be used according to the clinical setting and also provides modelling data on the impact of 
prevalence on performance. 
 
A potential weakness of our study is that a number of biopsies were not interpretable as they 
did not show NAFLD but there again this is representative of real-world examination of this 
technology. In addition, we did not establish whether repeat VTCE examination would have 
generated consistent readings as demonstrated recently20. 
 
In summary, this study confirms the high applicability/low failure rate of VTCE in a cohort 
of patients with potential NAFLD, and demonstrate that LSM readings are not influenced by 
other histological components or choice of probe. Finally, our study provides a 
comprehensive range of cut-offs for LSM and CAP depending on the value a clinician places 
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on false positive/false negatives as well as taking into account the prevalence of the degree of 
fibrosis. This will be critical for the roll-out of VTCE in a range of clinical settings. 
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Figure legends 
 
Figure 1. Study flow chart.  
Of 450 patients enrolled, 433 were eligible, 415 had the FibroScan examination performed 
and 404 had a valid FibroScan examination. Eventually 383 had a valid controlled attenuation 
parameter (CAP) measurements and steatosis grade assessed on liver biopsy (LB) and 373 
had a valid liver stiffness measurement (LSM) and fibrosis stage assessed on LB. 
 
Figure 2. Boxplot of (a) controlled attenuation parameter (CAP) versus steatosis grade, 
(b) liver stiffness measurement (LSM) versus fibrosis stage.  
(a) CAP values increase with increasing steatosis grade (Kruskal–Wallis test p < 10-16, 
Dunn's post hoc tests, p = 0.19 between CAP in S2 and CAP in S3, p < 10-3 otherwise); (b) 
LSM values increase significantly with increasing fibrosis stage (Kruskal-Wallis p < 10-16; 
Dunn's post hoc tests, p = 1 between LSM in F0 and LSM in F1, p < 0.05 otherwise).  
 
Figure 3. Boxplot of LSM versus fibrosis stage stratified by (a) probe type, (b) quartile 
of semi-quantitative steatosis percentage. 
The boxplot represent the LSM distribution for each fibrosis stage (a) according to the probe 
used. Patients were scanned either with the M or XL probe as proposed by the automatic 
probe recommendation tool. (b) stratified by steatosis amount: for each fibrosis stage, patients 
are stratified by steatosis quartile in the fibrosis stage.  
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
28 
 
Table legends 
 
Table 1. Patient characteristics 
 
Table 2. Diagnostic performance of controlled attenuation parameter (CAP) for 
steatosis grade greater or equal than 1, greater or equal than 2 and equal to 3. 
 
Table 3. Diagnostic performance of liver stiffness measurement (LSM) for each fibrosis 
stage greater or equal than 2, greater or equal than 3 and equal to 4. 
 
Table 4. Impact of prevalence of F≥F2 and F=4 on positive predictive value (PPV) and 
negative predictive value (NPV) for cut-offs. 
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Table 1. Patient characteristics 
Characteristic N Distribution Range 
Centre 383 
Birmingham: 102 (27%) 
Newcastle: 51 (13%) 
London: 52 (14%) 
Nottingham: 40 (10%) 
Plymouth: 48 (13%) 
Cambridge: 60 (16%) 
Oxford: 30 (8%)  
─ 
Age (years) 383 54 [18] [19-77] 
BMI (kg.m-2) 383 33.8 [9.2],  [19.5-53.2] 
Female gender 383 171 (45%) ─ 
Diabetes mellitus 383 193 (50%) ─ 
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Hypertension 383 207 (54%) ─ 
Hypercholesterolemia 383 199 (52%) ─ 
Platelets count (x109/L) 373 236 [84] [57-446] 
INR 361 1.08 [0.09] [0.81-2.54] 
AST (IU/L) 378 36 [25] [9-203] 
ALT (IU/L) 378 50 [40] [7-298] 
GGT (IU/L) 378 59 [88] [9-1718] 
Alkaline phosphatase (IU/L) 377 82 [40] [4-738] 
Albumin (g/dL) 379 4.5 [0.4] [3.6-5.5] 
Bilirubin (mg/dL) 378 0.50 [0.35] [0.12-3.96] 
Fasting glucose (mg/dL) 376 106 [51] [50-312] 
Total cholesterol (mg/dL) 363 179 [64] [80-274] 
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HDL cholesterol (mg/dL) 351 43 [17] [15-101] 
LDL cholesterol (mg/dL) 350 102 [51] [3-189] 
Triglyceride (mg/dL) 362 161 [92] [51-501] 
Ferritin (ng/mL) 378 134 [214] [7-4320] 
Urea (mg/dL) 378 29 [11] [12-84] 
Creatinine (mg/dL) 379 0.85 [0.22] [0.36-1.94] 
A2M (mg/dL) 376 205 [121] [91-523] 
Hyaluronic acid (ug/L) 379 40 [55] [19-1850] 
CRP (mg/dL) 378 0.31 [0.47] [0.02-7.53] 
CK18-M30 (IU/L) 369 415 [395] [74-1825] 
Time between FibroScan and 
liver biopsy (day) 
383 0 [7] [0-14] 
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XL probe 383 255 (67%) ─ 
LSM (kPa), range 1.5-75 kPa 383 8.8 [7.8] [1.7-75.0] 
CAP (dB/m), range 100-400 
dB/m 
380 336 [74] [100-400] 
Length of liver biopsy 
specimen (mm) 
383 23 [10] [5-60] 
Fibrosis stage 373 
F0: 62 (17%) 
F1: 86 (23%) 
F2: 85 (23%) 
F3: 106 (28%) 
F4: 34 (9%)  
─ 
Steatosis grade 383 
S0: 47 (12%) 
S1: 89 (23%) 
S2: 109 (28%) 
─ 
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S3: 138 (36%) 
Ballooning grade 383 
B0: 106 (28%) 
B1: 147 (38%) 
B2: 130 (34%) 
─ 
Lobular inflammation grade 383 
I0: 90 (23%)  
I1: 235 (61%)  
I2: 51 (13%)  
I3: 7 (2%) 
─ 
NAS score 383 
0-2: 90 (23%) 
3-4: 122 (32%) 
5-8: 171 (45%) 
─ 
Activity grade (according to 
SAF) 
383 
A0: 55 (14%)  
A1: 80 (21%)  
A2: 102 (27%)  
─ 
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A3: 110 (29%) 
A4: 36 (9%) 
Portal inflammation present 382 172 (45%) ─ 
Pathologists diagnosis 383 
Normal liver: 17 (4%) 
NAFL: 91 (24%) 
NASH: 242 (63%) 
Other: 33 (9%) 
─ 
Distribution is expressed as median [interquartile range] or figure (percentage). 
A2M: alpha-2 macroglobulin, ALT: alanine transaminase, AST: aspartate aminotransferase, BMI: body mass index, CK18-M30: cytokeratin 18 
neoepitope M30, CAP: controlled attenuation parameter, CRP: C-reactive protein, GGT: gamma-glutamyl transferase, HDL: high-density 
lipoprotein, INR: international normalized ratio, LDL: low-density lipoprotein, LSM: liver stiffness measurement, NAFL: non-alcoholic fatty 
liver, NAFLD: NAFL disease, NASH: non-alcoholic steato-hepatitis, NAS: NAFLD activity score. 
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Table 2. Diagnostic performance of controlled attenuation parameter (CAP) for steatosis grade greater or equal than 1, greater or equal 
than 2 and equal to 3. 
 S≥S1 (≥5% steatosis) S≥S2 (≥34% steatosis) S=S3 (≥67% steatosis) 
AUROC (95%CI) 0.87 (0.82-0.92) 0.77 (0.71-0.82) 0.70 (0.64-0.75) 
Prevalence (N) 0.88 (N=303) 0.64 (N=244) 0.36 (N=137) 
Youden 
 Index 
Cut-off (dB/m) 302 331 337 
Se (95%CI) 
TP/(TP+FN) 
Sp (95%CI) 
TN/(TN+FP) 
0.80 (0.75-0.84) 
(266/333) 
0.83 (0.69-0.92) 
(39/47) 
0.70 (0.63-0.75) 
(170/244) 
0.76 (0.68-0.83) 
(104/136) 
0.72 (0.63-0.79) 
(98/137) 
0.63 (0.56-0.69) 
(152/243) 
PPV (95% CI)  
NPV (95% CI) 
0.97 (0.94-0.98) 
0.37 (0.31-0.59) 
0.84 (0.78-0.88) 
0.58 (0.52-0.68) 
0.52 (0.45-0.62) 
0.80 (0.73-0.84) 
LR+ (95% CI) 4.69 (2.49-8.84) 2.96 (2.16-4.05) 1.91 (1.57-2.32)   
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LR- (95% CI) 0.24 (0.19-0.31) 0.40 (0.32-0.49) 0.46 (0.34-0.60) 
Se=0.90 
Cut-off (dB/m) 274 290 302 
Se (95%CI) 
TP/(TP+FN) 
Sp (95%CI) 
TN/(TN+FP) 
Se = 0.90 (0.87-0.93) 
(301/333) 
Sp = 0.60 (0.44-0.74) 
(28/47) 
Se = 0.90 (0.86-0.94) 
(220/244) 
Sp = 0.44 (0.36-0.53) 
(60/136) 
Se = 0.90 (0.83-0.94) 
(123/137) 
Sp = 0.38 (0.32-0.44) 
(92/243) 
PPV (95% CI) 
NPV (95% CI) 
PPV = 0.94 (0.90-0.96) 
NPV = 0.47 (0.38-0.62) 
PPV = 0.74 (0.67-0.82) 
NPV = 0.71 (0.62-0.78) 
PPV = 0.45 (0.38-0.61) 
NPV = 0.87 (0.79-0.90) 
LR+ (95% CI) 
LR- (95% CI) 
LR+ = 2.24 (1.58-3.17) 
LR- = 0.16 (0.11-0.24) 
LR+ = 1.61 (1.38-1.88) 
LR- = 0.22 (0.15-0.34) 
LR+ = 1.44 (1.29-1.62) 
LR- = 0.27 (0.16-0.45) 
Sp=0.90 
Cut-off (dB/m) 325 370 398 
Se (95%CI) 
TP/(TP+FN) 
Se = 0.66 (0.61-0.71]) 
(220/333) 
Se = 0.34 (0.28-0.40) 
(83/244) 
Se = 0.14 (0.09-0.21) 
(19/137) 
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Sp (95%CI) 
TN/(TN+FP) 
Sp = 0.90 (0.77-0.96) 
(42/47) 
Sp = 0.90 (0.83-0.94) 
(122/136) 
Sp = 0.90 (0.86-0.94) 
(219/243) 
PPV (95% CI) 
NPV (95% CI) 
PPV = 0.98 (0.95-0.98) 
NPV = 0.27 (0.23-0.55) 
PPV = 0.86 (0.77-0.89) 
NPV = 0.43 (0.36-0.59) 
PPV = 0.44 (0.34-0.56) 
NPV = 0.65 (0.52-0.75) 
LR+ (95% CI) 
LR- (95% CI) 
LR+ = 6.21 (2.70-14.27 
LR- = 0.38 (0.32-0.45) 
LR+ = 3.30 (1.95-5.59) 
LR- = 0.74 (0.66-0.82) 
LR+ = 1.40 (0.80-2.47) 
LR- = 0.96 (0.88-1.03) 
 
AUROC: area under the receiver operating curve, CI: confidence interval, FN: number of false negative, FP: number of false positive, LR-: 
negative likelihood ratio, LP+: positive likelihood ratio, NPV: negative predictive value, PPV: positive predictive value, S: steatosis, Se: 
sensitivity, Sp: specificity, TN: true negative, TP: true positive. 
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Table 3. Diagnostic performance of liver stiffness measurement (LSM) for each fibrosis stage greater or equal than 2, greater or equal 
than 3 and equal to 4. 
 F≥F2 F≥F3 F=F4 
AUROC (95%CI) HIS 0.80 (0.75-0.84) 0.89 (0.84-0.93) 
Prevalence (N) 0.60 (N=225) 0.38 (N=140) 0.09 (N=34) 
Youden 
 Index 
Cut-off (kPa) 8.2 9.7 13.6 
Se (95%CI) 
TP/(TP+FN)  
Sp (95%CI) 
TN/(TN+FP) 
Se = 0.71 (0.64-0.77) 
(159/225) 
Sp = 0.70 (0.62-0.77) 
(103/148) 
Se = 0.71 (0.62-0.78) 
(99/140) 
Sp = 0.75 (0.69-0.80) 
(174/233) 
Se = 0.85 (0.69-0.95) 
(29/34) 
Sp = 0.79 (0.74-0.83) 
(267/339) 
PPV (95% CI) 
NPV (95% CI) 
PPV = 0.78 (0.71-0.83) 
NPV = 0.61 (0.54-0.69) 
PPV = 0.63 (0.55-0.71) 
NPV = 0.81 (0.74-0.85) 
PPV = 0.29 (0.24-0.57) 
NPV = 0.98 (0.95-0.99) 
LR+ (95% CI) LR+ = 2.32 (1.80-3.01) LR+ = 2.79 (2.19-3.57) LR+ = 4.02 (3.13-5.15) 
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LR- (95% CI) LR- = 0.42 (0.34-0.53) LR- = 0.39 (0.30-0.51) LR- = 0.19 (0.08-0.42) 
Se=0.90 
Cut-off (kPa) 6.1 7.1 10.9 
Se (95%CI) 
TP/(TP+FN)  
Sp (95%CI) 
TN/(TN+FP) 
Se = 0.90 (0.86-0.94) 
(203/225) 
Sp = 0.38 (0.30-0.46) 
(56/148) 
Se = 0.90 (0.84-0.94) 
(126/140) 
Sp = 0.50 (0.43-0.56) 
(116/233) 
Se = 0.91 (0.76-0.98) 
(31/34) 
Sp = 0.70 (0.64-0.74) 
(236/339) 
PPV (95% CI) 
NPV (95% CI) 
PPV = 0.69 (0.61-0.78) 
NPV = 0.72 (0.62-0.78) 
PPV = 0.52 (0.45-0.67) 
NPV = 0.89 (0.83-0.92) 
PPV = 0.23 (0.19-0.61) 
NPV = 0.99 (0.96-0.99) 
LR+ (95% CI) 
LR- (95% CI) 
LR+ = 1.45 (1.27-1.66) 
LR- = 0.26 (0.17-0.40) 
LR+ = 1.79 (1.56-2.06) 
LR- = 0.20 (0.12-0.34) 
LR+ = 3.00 (2.48-3.64) 
LR- = 0.13 (0.04-0.37) 
Sp=0.90 
Cut-off (kPa) 12.1 14.1 20.9 
Se (95%CI) 
TP/(TP+FN) 
Se = 0.44 (0.38-0.51) 
(100/225) 
Se = 0.48 (0.39-0.56) 
(67/140) 
Se = 0.59 (0.41-0.75) 
(20/34) 
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Sp (95%CI) 
TN/(TN+FP) 
Sp = 0.91 (0.85-0.95) 
(134/148) 
Sp = 0.90 (0.86-0.94) 
(210/233) 
Sp = 0.90 (0.86-0.93) 
(305/339) 
PPV (95% CI) 
NPV (95% CI) 
PPV = 0.88 (0.80-0.90) 
NPV = 0.52 (0.45-0.67) 
PPV = 0.74 (0.65-0.80) 
NPV = 0.74 (0.67-0.82) 
PPV = 0.37 (0.29-0.56) 
NPV = 0.96 (0.91-0.97) 
LR+ (95% CI) 
LR- (95% CI) 
LR+ = 4.70 (2.79-7.90) 
LR- = 0.61 (0.54-0.70) 
LR+ = 4.85 (3.17-7.41) 
LR- = 0.58 (0.49-0.68) 
LR+ = 5.87 (3.83-8.97) 
LR- = 0.46 (0.31-0.69) 
 
AUROC: area under the receiver operating curve, CI: confidence interval, FN: number of false negative, FP: number of false positive, LR-: 
negative likelihood ratio, LP+: positive likelihood ratio, NPV: negative predictive value, PPV: positive predictive value, Se: sensitivity, Sp: 
specificity, TN: true negative, TP: true positive. 
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Table 4. Impact of prevalence of F≥F2, F≥F3 and F=4 on positive predictive value (PPV) and negative predictive value (NPV) 
together with their (95% confidence interval) of LSM for the cutoff for Se=0.90, for the Youden index cutoff and for the cutoff 
for Sp=0.90. 
 Prevalence Justification Cutoff for Se=0.90 Youden index cutoff Cutoff for Se=0.90 
Diagnostic 
of 
F≥F2 
- - Cutoff = 6.1 kPa Cutoff = 8.2 kPa Cutoff = 12.1 kPa 
60% 
Actual prevalence in 
our population 
PPV=69% (66%-71%) 
NPV=72% (62%-80%) 
PPV=78% (73%-82%) 
NPV=61% (56%-67%) 
PPV=88% (81%-92%) 
NPV=52% (49%-55%) 
40% 
Estimated prevalence in 
diabetic clinic 42 
PPV=49% (46%-53%) 
NPV=85% (79%-90%) 
PPV=61% (54%-67%) 
NPV=78% (74%-82%) 
PPV=76% (65%-84%) 
NPV=71% (68%-74%) 
7% 
Estimated prevalence in 
general population 40 
PPV=10% (9%-11%) 
NPV=98% (97%-99%) 
PPV=15% (12%-18%) 
NPV=97% (96%-98%) 
PPV=26% (17%-37%) 
NPV=96% (95%-96%) 
Diagnostic 
of 
F≥F3 
- - Cutoff = 7.1 kPa Cutoff = 9.7 kPa Cutoff = 14.1 kPa 
38% 
Actual prevalence in 
our population 
PPV = 52% (45%-67%) 
NPV = 89% (83%-92%) 
PPV = 63% (55%-71%) 
NPV = 81% (74%-85%) 
PPV = 74% (65%-80%) 
NPV = 74% (67%-82%) 
18% 
Estimated prevalence in 
diabetic clinic 42 
PPV=28% (24%-32%) 
NPV=96% (92%-98%) 
PPV=38% (30%-46%) 
NPV=92% (89%-94%) 
PPV=52% (37%-66%) 
NPV=89% (87%-91%) 
2% 
Estimated prevalence in 
general population 41 
PPV=4% (3%-4%) 
NPV=99.6% (99.2%-99.8%) 
PPV=5% (4%-7%) 
NPV=99.2% (98.9%-99.4%) 
PPV=9% (5%-15%) 
NPV=98.8% (98.6%-99.1%) 
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Diagnostic 
of 
F=F4 
- - Cutoff = 10.9 kPa Cutoff = 13.6 kPa Cutoff = 20.9 kPa 
9% 
Actual prevalence in 
our population 
PPV=23% (20%-26%) 
NPV=98.7% (96.5%-99.6%) 
PPV=28% (24%-34%) 
NPV=98.2% (96.0%-99.2) 
PPV=37% (27%-47%) 
NPV=95.7% (93.7%-97.1%) 
3% 
Estimated prevalence in 
population at risk of 
liver disease 41 
PPV=8% (7%-10%) 
NPV=99.6% (98.9%-99.9%) 
PPV=11% (9%-14%) 
NPV=99.4% (98.7%-99.8%) 
PPV=15% (11%-22%) 
NPV=98.6% (97.9%-99.1%) 
1% 
Estimated prevalence in 
general population 41 
PPV=3% (2%-4%) 
NPV=99.9% (99.6%-100%) 
PPV=4% (3%-5%) 
NPV=99.8% (99.6%-99.9%) 
PPV=6% (4%-8%) 
NPV=99.5% (99.3%-99.7%) 
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Supplementary Methods 
Influence of the consequences of diagnostic error and of disease prevalence on LSM cut-offs:  
further analysis on cut-offs was performed for the diagnostic of F≥F2 and F=F4 to take into account 
the consequences of incorrect classifications on the diagnosis and the disease prevalence. This can 
be achieved by finding the cut-off value (C) that minimizes the misclassification-cost term
1, 2
: 
() = 	


1 − () +	(1 − )(1 − ())    (Eq. 3) 
where:  is the cost associated with a false negative (FN),  is the cost associated with a false 
positive (FP), P is the prevalence. Of note (1 − ) is the probability of false-negative Prob(FN) and 
(1 − )(1 − ) is the probability of false-positive Prob(FP). For the diagnostic of F≥F2, a FP is 
worse than a FN, therefore we computed the cut-off value for a cost of an FP 2 times, 5 times and 10 
times the cost of an FN
1, 2
. For the diagnostic of F=4, a FN is worse than a FP, therefore we computed 
the cut-off value for a cost of an FN 2 times, 5 times and 10 times the cost of an FP. Finally, we 
assessed the impact of disease prevalence on the computed cut-offs by varying the prevalence in 
(Eq. 1) from 5% to 70% for F≥F2 and from 0% to 10% for F=F4.  
 
Supplementary Results 
Using clinical consequences to determine optimal cut-offs 
Understanding the consequences of diagnostic error, which will vary depending on the clinical 
setting, can make a major impact on the choice of cut-offs. In Supplementary Table 11 we modelled 
several scenarios for a diagnosis of F≥F2 and then for F=F4. In a low prevalence setting there may be 
a greater priority on reducing false positive rate and thus we examined scenarios where the cost of a 
false positive (FP) was 2 times, 5 times and 10 times worse than a false negative (FN). In another 
setting there may be prioritisation on not missing a patient with cirrhosis, and here the cost of a FN 2 
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times, 5 times and 10 times worse than a FP. The impact of the prevalence on those computed cut-
offs is given in Supplementary Figure 3 by varying the prevalence from 5% to 70% for F≥F2 and from 
0% to 10% for F=F4. 
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Supplementary Table 1. Standards for Reporting of Diagnostic Accuracy (STARD) check-list 
 Section & Topic No Item 
Reported on 
page # 
 TITLE OR 
ABSTRACT 
   
  1 Identification as a study of diagnostic accuracy using at least one 
measure of accuracy (such as sensitivity, specificity, predictive 
values, or AUC) 
1 
 ABSTRACT    
  2 Structured summary of study design, methods, results, and 
conclusions (for specific guidance, see STARD for Abstracts) 
6 
 INTRODUCTION    
  3 Scientific and clinical background, including the intended use and 
clinical role of the index test 
8-9 
  4 Study objectives and hypotheses 9 
 METHODS    
 Study design 5 Whether data collection was planned before the index test and 
reference standard were performed (prospective study) or after 
(retrospective study) 
10 
 Participants 6 Eligibility criteria  11 
  7 On what basis potentially eligible participants were identified 
(such as symptoms, results from previous tests, inclusion in 
registry) 
10 
  8 Where and when potentially eligible participants were identified 
(setting, location and dates) 
10 
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  9 Whether participants formed a consecutive, random or 
convenience series 
10 
 Test methods 10a Index test, in sufficient detail to allow replication 13-14 
  10b Reference standard, in sufficient detail to allow replication 12-13 
  11 Rationale for choosing the reference standard (if alternatives 
exist) 
10 
  12a Definition of and rationale for test positivity cut-offs or result 
categories of the index test, distinguishing pre-specified from 
exploratory 
14-16 
  12b Definition of and rationale for test positivity cut-offs or result 
categories of the reference standard, distinguishing pre-specified 
from exploratory 
12-13 
  13a Whether clinical information and reference standard results were 
available to the performers/readers of the index test 
13 
  13b Whether clinical information and index test results were available 
to the assessors of the reference standard 
12 
 Analysis 14 Methods for estimating or comparing measures of diagnostic 
accuracy 
14-15 
  15 How indeterminate index test or reference standard results were 
handled 
16 
  16 How missing data on the index test and reference standard were 
handled 
16 
  17 Any analyses of variability in diagnostic accuracy, distinguishing 
pre-specified from exploratory 
14-16 
  18 Intended sample size and how it was determined 14 
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 RESULTS    
 Participants 19 Flow of participants, using a diagram Figure 1 
  20 Baseline demographic and clinical characteristics of participants Table 1 
  21a Distribution of severity of disease in those with the target 
condition 
18-19 & Table 
1  
  21b Distribution of alternative diagnoses in those without the target 
condition 
NA 
  22 Time interval and any clinical interventions between index test 
and reference standard 
Table 1 
 Test results 23 Cross tabulation of the index test results (or their distribution)  
by the results of the reference standard 
Table 2 & 
Table 3 
  24 Estimates of diagnostic accuracy and their precision (such as 95% 
confidence intervals) 
Table 2 & 
Table 3 
  25 Any adverse events from performing the index test or the 
reference standard 
17-18 
 DISCUSSION    
  26 Study limitations, including sources of potential bias, statistical 
uncertainty, and generalisability 
23-26 
  27 Implications for practice, including the intended use and clinical 
role of the index test 
23-26 
 OTHER 
INFORMATION 
   
  28 Registration number and name of registry 7 & 10 
  29 Where the full study protocol can be accessed Available upon  
request to the  
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corresponding  
author  
  30 Sources of funding and other support; role of funders 2 
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Supplementary Table 2. Histological description of patients with histological diagnoses other than 
NAFLD or normal liver (including those for whom it was not possible to stage fibrosis according to 
the NASH CRN scoring system (F=NA)). 
 
Number 
of cases 
Pathology diagnosis Pathology comment SAF score
*
 
4 Cryptogenic cirrhosis Burnt out NASH or other 
aetiology 
N=3: S0A0F4 
N=1: S0A1F4 
2 Inflammatory 
cirrhosis 
Other disease N=2: S0A2F4 
7 Fibrosis without any 
sign of NAFLD 
Burnt out NASH or other 
aetiology 
N=3: S0A0F2  
N=3: S0A0F3  
N=1: S0A1F3  
3 NAFLD and associated 
lesions 
 Granuloma or lesions 
suggesting active chronic 
hepatitis  
N=1: S2A2F3 
N=1: S1A1F=NA 
N=1: S1A2F=NA 
17 Not NAFLD but not 
normal liver 
Inflammatory lesion or other 
cause. None have steatosis, 
all have portal inflammation 
N=1: S0A0F0   
N=2: S0A0F1 
N=1: S0A1F0  
N=4: S0A1F1  
N=1: S0A1F2  
N=1: S0A0F=NA 
N=1: S0A0F=NA  
N=2: S0A1F=NA 
N=2: S0A1F=NA   
N=1: S0A1F=NA 
N=1: S0A2F=NA 
*: SAF score is given in patients for whom fibrosis could be staged. For others, only steatosis and 
activity grade are given, fibrosis stage is mentioned as F = NA. 
A: activity, F: fibrosis, NA: not applicable, NAFLD: non-alcoholic fatty liver disease, NASH: non-
alcoholic steato-hepatitis, S: steatosis. 
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Supplementary Table 3: AUROC (95% CI) for the diagnostic of steatosis grade ≥ 1, ≥ 2 and = to 3 
when dichotomizing patients by their IQR of CAP value (< and ≥ 30 dB/m and (< and ≥ 40 dB/m). P-
value corresponds to the AUROC comparison using Delong test. 
 
 
 
  
 
N 
(proportion) 
AUROC 
(95%CI) 
 for S≥S1 
P 
value 
AUROC 
(95%CI) 
 for S≥S2 
P 
value 
AUROC 
(95%CI) 
for S=S3 
P 
value 
IQR 
CAP<30 
164 (43%) 
0.88  
(0.77-0.99) 
0.60 
0.69 
(0.59-0.79) 
0.09 
0.64  
(0.56-0.73) 
0.01 
IQR 
CAP≥30 
216 (57%) 
0.85  
(0.78-0.91) 
0.80  
(0.74-0.85) 
0.78  
(0.72-0.84) 
 
IQR 
CAP<40 
232 (61%) 
0.87  
(0.79-0.95) 
0.91 
0.74  
(0.66-0.82) 
0.51 
0.68  
(0.61-0.74) 
0.07 
IQR 
CAP≥40 
148 (39%) 
0.85  
(0.78-0.91) 
0.80  
(0.74-0.85) 
0.78  
(0.72-0.84) 
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Supplementary Table 4: Diagnostic performance of controlled attenuation parameter (CAP) for 
each steatosis grade ≥1, ≥2 and = to 3 stratified by ALT value.  
 S≥1 S≥2 S=3 
Stratum 1 
AUROC (95%CI) for  
ALT≤ULN  
0.86 (0.80-0.93) 0.74 (0.67-0.82) 0.73 (0.65-0.81) 
Pr=0.86 Pr=0.56 Pr=0.22 
Stratum 2 
AUROC (95%CI) for 
 ULN>ALAT≤2*ULN 
0.87 (0.73-1.00) 0.78 (0.68-0.88) 0.69 (0.60-0.77) 
Prevalence=0.92 Prevalence=0.75 Prevalence=0.49 
Stratum 3  
AUROC (95%CI) for 
 ALAT>2*ULN 
0.95 (0.88-1.00) 0.84 (0.68-1.00) 0.67 (0.48-0.85) 
Prevalence=0.95 Prevalence=0.80 Prevalence=0.55 
AUROC comparison Stratum 1/2: P=0.89 
Stratum 1/3: P=0.08 
Stratum 2/3: P=0.34 
Stratum 1/2: P=0.53 
Stratum 1/3: P=0.29 
Stratum 2/3: P=0.55 
Stratum 1/2: P=0.47 
Stratum 1/3: P=0.54 
Stratum 2/3: P=0.83 
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Supplementary Table 5: AUROC of CAP, HSI and FLI for the diagnosis of S≥1, S≥2 and S=3. P value 
corresponds to the AUROC comparison with CAP AUROC using Delong test. 
   S≥1 S≥2 S=3 
CAP AUROC 0.87 (0.81-0.92) 0.77 (0.72-0.83) 0.70 (0.65-0.75) 
HSI AUROC 0.63 (0.55-0.71) 0.63 (0.58-0.69) 0.59 (0.53-0.65) 
P value <10
-8
 <10
-5
 0.01 
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Supplementary Table 6. Comparison of patient characteristics between the 10 patients with 
fibrosis not staged according to the NASH CRN scoring system and the 373 patients used for 
fibrosis staging analysis (Figure 1). 
All bio-clinical parameters from Table 1 were tested. Only those with a P-value < 0.20 for the 
comparison are represented in the table. Distribution is expressed as median [interquartile range] or 
figure (percentage). Comparison was performed using Mann-Whitney U test for continuous variables 
and using χ2 test or Fisher-exact test, as applicable for binary or categorical variables. 
Characteristic 
N=10 
Patients with fibrosis not 
staged according to 
NASH CRN 
N=373 
Patients with fibrosis 
staged according to NASH 
CRN 
P-value 
Centre 
Birmingham: 1 (10%) 
Newcastle: 1 (10%) 
London: 0 (0%) 
Nottingham: 0 (0%) 
Plymouth: 6 (60%) 
Cambridge: 0 (0%) 
Oxford: 2 (20%)  
Birmingham: 101 (27%) 
Newcastle: 50 (13%) 
London: 52 (14%) 
Nottingham: 40 (11%) 
Plymouth: 42 (11%) 
Cambridge: 60 (16%) 
Oxford: 28 (8%)  
<10
-3
 
Female gender 8 (80%) 163 (44%) 0.05 
Alkaline phosphatase 
(IU/L) 
161 [100] 81 [38] 0.006 
Fasting glucose (mg/dL) 87 [15] 107 [52] 0.02 
HDL cholesterol (mg/dL) 54 [14] 43 [17] 0.06 
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Ferritin (ng/mL) 111 [92] 135 [216] 0.15 
Creatinine (mg/dL) 0.76 [0.14] 0.86 [0.22] 0.05 
CK18-M30 (IU/L) 310 [210] 416 [402] 0.09 
CAP (dB/m) 242 [63] 337 [73] <10
-3
 
Steatosis grade 
S0: 8 (80%) 
S1: 2 (20) 
S2: 0 (0%) 
S3: 0 (0%) 
S0: 39 (10%) 
S1: 87 (23%) 
S2: 109 (29%) 
S3: 138 (37%) 
<10
-6
 
Ballooning grade 
B0: 9 (90%) 
B1: 1 (10%) 
B2: 0 (0%) 
B0: 97 (26%) 
B1: 146 (39%) 
B2: 130 (35%) 
<10
-4
 
NAS score 
0-2: 8 (80%) 
3-4: 2 (20%) 
5-8: 0 (0%) 
0-2: 82 (22%) 
3-4: 120 (32%) 
5-8: 171 (46%) 
<10
-4
 
Activity grade 
A0: 2 (20%)  
A1: 6 (60%)  
A2: 2 (20%)  
A3: 0 (0%) 
A4: 0 (0%) 
A0: 53 (14%)  
A1: 74 (20%)  
A2: 100 (27%)  
A3: 110 (29%) 
A4: 36 (10%) 
0.02 
Portal inflammation 
present 
10 (100%) 162 (44%) <10
-3
 
Pathologists diagnostic Normal liver: 0 (0%) Normal liver: 17 (5%) <10
-10
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NAFL: 0 (0%) 
NASH: 0 (0%) 
Other: 10 (100%) 
NAFL: 91 (24%) 
NASH: 242 (65%) 
Other: 23 (6%) 
 
GGT: gamma-glutamyl transferase, HDL: high-density lipoprotein, NAFL: non-alcoholic fatty liver, 
NAFLD: NAFL disease, NASH: non-alcoholic steato-hepatitis, NAS: NAFLD Activity Score. 
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Supplementary Table 7: AUROC (95% CI) for the diagnosis of fibrosis stage ≥2, ≥3 and = to 4 in all 
patients and patients with Fibroscan fulfilling Boursier’s criteria
3
. 
 
 N  F≥F2 F≥F3 F=F4 
Patients with 
Fibroscans fulfilling 
Boursier’s criteria 
331 AUROC=0.78 
(0.73-0.83) 
Prevalence=0.70 
AUROC=0.80 
(0.75-0.86) 
Prevalence=0.53 
AUROC=0.90 
(0.86-0.95) 
Prevalence=0.07 
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Supplementary Table 8: Diagnostic performance of liver stiffness measurement (LSM) for each 
fibrosis stage ≥2, ≥3 and = to 4 stratified by ALT value. The AUROC comparison was performed 
using Delong test.  
 
F≥2 F≥3 F=4 
Stratum 1 
AUROC (95%CI) for  
ALT≤ULN  
0.80 (0.71-0.88) 0.81 (0.72-0.90) 0.87 (0.78-0.95) 
Prevalence=0.46 Prevalence =0.34 Prevalence =0.10 
Stratum 2 
AUROC (95%CI) for 
 ULN>ALAT≤2*ULN 
0.75 (0.67-0.83) 0.77 (0.70-0.85) 0.93 (0.89-0.98) 
Prevalence =0.64 Prevalence =0.40 Prevalence =0.09 
Stratum 3 
AUROC (95%CI) for 
 ALAT>2*ULN 
0.79 (0.69-0.89) 0.81 (0.71-0.90) 0.86 (0.72-0.99) 
Prevalence =0.68 Prevalence =0.36 Prevalence =0.07 
AUROC comparison 
Stratum 1/2: P=0.41 
Stratum 1/3: P=0.93 
Stratum 2/3: P=0.51 
Stratum 1/2: P=0.58 
Stratum 1/3: P=0.96 
Stratum 2/3: P=0.62 
Stratum 1/2: P=0.17 
Stratum 1/3: P=0.90 
Stratum 2/3: P=0.30 
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Supplementary Table 9: AUROC of LSM, Fib4 and NFS for the diagnosis of fibrosis stage ≥2, ≥3 and 
= to 4. P value corresponds to AUROC comparison with LSM AUROC using Delong test. 
  F≥2 F≥3 F=4 
LSM AUROC 0.77 (0.72-0.82) 0.80 (0.75-0.85) 0.90 (0.85-0.94) 
Fib4 
AUROC 0.72 (0.67-0.78) 0.78 (0.73-0.83) 0.84 (0.78-0.91) 
P value 0.09 0.31 0.03 
NFS 
AUROC 0.69 (0.63-0.74) 0.75 (0.70-0.80) 0.81 (0.73-0.90) 
P value 0.006 0.07 0.01 
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Supplementary Table 10: Performance comparison of LSM, Fib4 and NFS using dual-cutoff approach for the diagnosis of advanced fibrosis (F≥3). 
LSM Fib4 NFS 
Lower cut-off 
(< 7.1 kPa) 
Grey zone 
Upper cut-off 
(≥14.1 kPa) 
Lower cut-off 
(<1.30) 
Grey zone 
Upper cut-off 
(≥3.25) 
Lower cut-off 
(<-1.455) 
Grey zone 
Upper cut-off 
(≥0.676) 
N = 127 (35%) N = 148 (41%) N = 87 (24%) N = 209 (58%) N = 131 (36%) N = 22 (6%) N = 153 (42%) N = 170 (47%) N = 39 (11%) 
Sp=0.50 
─ 
Se=0.48 Sp=0.73 
─ 
Se=0.14 Sp=0.56 
─ 
Se=0.22 
NPV=0.90 PPV=0.74 NPV=0.80 PPV=0.86 NPV=0.84 PPV=0.74 
F<3: 114 (50%) F<3: 93 (41%) F<3: 22 (10%) F<3: 168 (73%) F<3: 58 (25%) F<3: 3 (1%) F<3: 128 (56%) F<3: 91 (40%) F<3: 10 (4%) 
F≥3: 13 (10%) F≥3: 55 (41%) F≥3: 65 (49%) F≥3: 41 (31%) F≥3: 73 (55%) F≥3: 19 (14%) F≥3: 25 (19%) F≥3: 79 (59%) F≥3:29 (22%) 
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Supplementary Table 11: Diagnostic performance of liver stiffness measurement (LSM) taking into account the consequences of diagnostic error: for the 
diagnostic of F≥F2 with a cost false positive (FP) 2 times, 5 times and 10 times worse than a false negative (FN); for the diagnostic of F=F4 with a cost FN 2 
times, 5 times and 10 times worse than a FP. 
 F≥F2 F=F4 
Cut-off 
FP 2 times worse 
than FN 
10.3 
FN 2 times 
worse than FP 
27.4 
Se / Sp Se=0.55 / Sp=0.85 Se=0.41 / Sp=0.97 
PPV / NPV PPV=0.85 / NPV=0.55 PPV=0.61 / NPV=0.94 
LR+ / LR- LR+=3.68 / LR-=0.53 LR+=15.51 / LR-=0.60 
CC 0.67 0.92 
FP / FN FP=22 / FN=102 FP=9 / FN=20 
Cut-off 
FP 5 times worse 
than FN 
16.8 
FN 5 times 
worse than FP 
19.8 
Se / Sp Se=0.30 / Sp=0.96 Se=0.65 / Sp=0.89 
PPV / NPV PPV=0.92 / NPV=0.47 PPV=0.37 / NPV=0.96 
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LR+ / LR- LR+=7.35 / LR-=0.73 LR+=5.93 / LR-=0.40 
CC 0.56 0.87 
FP / FN FP=6 / FN=158 FP=37 / FN=12 
Cut-off 
FP 10 times 
worse than FN 
23.3 
FN 10 times 
worse than FP 
C=13.6 
Se Se=0.15 / Sp=0.99 Se=0.85 / Sp=0.79 
PPV / NPV PPV=0.94 / NPV=0.43 PPV=0.29 / NPV=0.98 
LR+ / LR- LR+=11.18 / LR-=0.86 LR+=4.02 / LR-=0.19 
CC 0.48 0.79 
FP / FN FP=2 / FN=191 FP=72 / FN=5 
 
AUROC: area under the receiver operating curve, CC: proportion of correctly classified, F: fibrosis, FN: number of false negative, FP: number of false 
positive, LR-: negative likelihood ratio, LP+: positive likelihood ratio, NPV: negative predictive value, PPV: positive predictive value, Se: sensitivity, Sp: 
specificity. 
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Supplementary Table 12: Impact of rounding cut-offs from Table  (Impact of prevalence of F≥F2, F≥F3 and F=4) on positive predictive value (PPV) and 
negative predictive value (NPV) of LSM for cut-offs for Se=0.90, Youden index cutoff and Sp=0.90). 
 
 Prevalence Justification Cutoff for Se=0.90 Youden index cutoff Cutoff for Se=0.90 
Diagnosis 
of 
F≥F2 
- - Cutoff = 6.1 kPa   Rounded 
cutoff = 6.0 kPa 
Cutoff = 8.2 kPa  Rounded 
cutoff = 8.0 kPa 
Cutoff = 12.1 kPa  Rounded 
cutoff = 12.0 kPa 
60% Actual prevalence in 
our population 
PPV=69% / 
NPV=72% 
PPV=69% / 
NPV=72% 
PPV=78% / 
NPV=61% 
 
PPV=77% / 
NPV=61% 
PPV=88% / 
NPV=52%  
PPV=88% / 
NPV=52% 
40% Estimated prevalence 
in diabetic clinic 
4
 
PPV=49% / 
NPV=85% 
PPV=49% / 
NPV=85% 
PPV=61% / 
NPV=78% 
PPV=59% / 
NPV=78% 
PPV=76% / 
NPV=71% 
PPV=76% / 
NPV=71% 
7% Estimated prevalence 
in general population 
5
 
PPV=10% / 
NPV=98% 
PPV=10% / 
NPV=98% 
PPV=15% / 
NPV=97%  
 
PPV=14% / 
NPV=97% 
PPV=26% / 
NPV=96% 
PPV=26% / 
NPV=96% 
Diagnosis - - Cutoff = 7.1 kPa  Rounded 
cutoff = 7.0 kPa 
Cutoff = 9.7 kPa  Rounded 
cutoff = 10.0 kPa 
Cutoff = 14.1 kPa  Rounded 
cutoff = 14.0 kPa 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
of 
F≥F3 
38% Actual prevalence in 
our population 
PPV=52% / PPV= 
89% 
PPV=52% / 
PPV=89% 
PPV=63% / 
NPV=81% 
PPV=63% / 
NPV=79% 
PPV = 74% / NPV 
= 74% 
PPV=74% / 
NPV=74% 
18% Estimated prevalence 
in diabetic clinic 
4
 
PPV=28% / 
NPV=96% 
PPV=28% / 
PPV=96% 
PPV=38% / 
NPV=92% 
PPV=38% / 
NPV=91% 
PPV=52% / 
NPV=89%  
PPV=52% / 
NPV=89% 
2% Estimated prevalence 
in general population 
6
  
PPV=4% / 
NPV=99.6%  
PPV=4% / 
PPV=99.5% 
PPV=5% / 
NPV=99.2%  
PPV=5% / 
NPV=99.1% 
PPV=9% / 
NPV=98.8%  
PPV=9% / 
NPV=98.8% 
Diagnosis 
of 
F=F4 
- - Cutoff = 10.9 kPa Rounded 
cutoff = 11.0 kPa 
Cutoff = 13.6 kPa Rounded 
cutoff = 14.0 kPa 
Cutoff = 20.9 kPa  Rounded 
cutoff = 21.0 kPa 
9% Actual prevalence in 
our population 
PPV=23% / 
NPV=98.7% 
PPV=23% / NPV 
=98.3% 
PPV=28% / 
NPV=98.2% 
PPV=29 / 
NPV=97.2% 
PPV=37% / 
NPV=95.7% 
PPV=38% / 
NPV=95.6% 
3% Estimated prevalence 
in population at risk of 
liver disease 
6
 
PPV=8% / 
NPV=99.6% 
PPV = 8% / 
NPV=99.5% 
PPV=11% / 
NPV=99.4%  
PPV=11% / 
NPV=99.1% 
PPV=15% / 
NPV=98.6% 
PPV=16% / 
NPV=98.6% 
1% Estimated prevalence PPV=3% / PPV=3% / PPV=4% / PPV=4% / PPV=6% / PPV=6% / 
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in general population 
6
 NPV=99.9% NPV=99.8% NPV=99.8% NPV=99.7% NPV=99.5% NPV=99.5% 
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Supplementary Table 13: Comparison of the main results from Siddiqui et al.
7
 and from the 
present study. 
 
   Present study Siddiqui et al.
7
 study 
Patients main 
characteristics
*
 
N 384 398 
Age (year) 54 [18] 51±11 
Female gender 45% 68% 
BMI (kg.m-2) 33.8 [9.2] 34.4±6.4 
AST (IU/L) 36 [25] 49±37 
ALT (IU/L) 50 [40] 64±44 
Diagnostic 
performance 
of LSM 
F≥F2 
Prevalence 0.60 0.51 
AUROC (95% CI) 0.77 (0.72-0.82) 0.79 (0.74-0.83) 
Cut-off for Youden’s index  8.2 kPa 8.6 kPa 
Cut-off for Se=0.90 6.1 kPa 5.6 kPa 
Cut-off for Sp=0.90 12.1 kPa 11.9 kPa 
F≥F3 
Prevalence 0.38 0.32 
AUROC (95% CI) 0.80 (0.75-0.84) 0.83 (0.79-0.87) 
Cut-off for Youden’s index  9.7 kPa 8.6 kPa 
Cut-off for Se=0.90 7.1 kPa 6.5 kPa 
Cut-off for Sp=0.90 14.1 kPa 12.1 kPa 
F=F4 
Prevalence 0.09 0.09 
AUROC (95% CI) 0.89 (0.84-0.93) 0.93 (0.90-0.97) 
Cut-off for Youden’s index  13.6 kPa 13.1 kPa 
Cut-off for Se=0.90 10.9 kPa 12.1 kPa 
Cut-off for Sp=0.90 20.9 kPa 14.9 kPa 
Diagnostic 
performance 
of CAP 
S≥S1 
Prevalence 0.88 0.95 
AUROC (95% CI) 0.87 (0.82-0.92) 0.76 (0.64-0.89) 
Cut-off for Youden’s index  302 dB/m 285 dB/m 
Cut-off for Se=0.90 274 dB/m 263 dB/m 
Cut-off for Sp=0.90 325 dB/m 353 dB/m 
S≥S2 
Prevalence 0.64  0.58 
AUROC (95% CI) 0.77 (0.71-0.82) 0.70 (0.64-0.75) 
Cut-off for Youden’s index  331 dB/m 311 dB/m 
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Cut-off for Se=0.90 290 dB/m 280 dB/m 
Cut-off for Sp=0.90 370 dB/m 367 dB/m 
S=S3 
Prevalence 0.36 0.27 
AUROC (95% CI) 0.70 (0.64-0.75) 0.58 (0.51-0.64) 
Cut-off for Youden’s index  337 dB/m 306 dB/m 
Cut-off for Se=0.90 302 dB/m 274 dB/m 
Cut-off for Sp=0.90 398 dB/m 380 dB/m 
 
*: results are given as median [inter-quartile range] for the present study and as mean±standard 
deviation for the Siddiqui et al.
7
 study.  
AUROC: area under the receiver operating curve, ALT: alanine transaminase, AST: aspartate 
aminotransferase, BMI: body mass index, CAP: controlled attenuation parameter, CI: confidence 
interval, F: fibrosis, LSM: liver stiffness measurement, S: steatosis, Se: sensitivity, Sp: specificity. 
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Supplementary Table 14: Published Youden cutoffs in NAFLD studies, except for Siddiqui et al
7
 
Reference N BMI (kg.m
-2
) Probe usage 
Diagnostic 
target 
Prevalence AUC 
Youden cutoff 
(kPa) 
Se/Sp 
Chen et al.
8
 111 40.3 
M or XL probe according to 
manufacturer’s recommendations. 
F≥F2 0.36 0.91 7.8  82/78  
F≥F3 0.20 0.87 7.6  84/64  
Imajo et al.
9
 127 28.1 M only 
F≥F2 0.54 0.82 11.0  65/89  
F≥F3 0.32 0.88 11.4  86/84  
F=F4 0.08 0.92 14.0  100/76  
Petta et al.
10
 324 
40% of patients 
>30 
M only 
F≥F2 0.58 0.81 8.5  74/74  
F≥F3 0.36 0.86 10.1  78/78  
Kumar et al.
11
 120 26.1 M only 
F≥F2 0.45 0.85 
7.0 
 
77/78 
 
F≥F3 0.23 0.94 
9.0 
 
85/88 
 
F=F4 0.08 0.96 
11.8 
 
90/88 
 
Naveau et al.
12
  100 42.3 
M or XL probe according to 
manufacturer’s 
recommendations 
F≥F2 0.22 0.81 7.6 73/78 
F≥F3 0.09 0.85 7.6 100/74 
Mahadeva et al.
13
  120 33% of patients M only F≥F2 0.57 0.67 6.9 59/69 
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>30 F≥F3 0.22 0.77 7.1 70/67 
F=F4 0.06 0.95 11.3 88/89 
Tapper et al.
14
 120 31.3 M only F≥F3 0.18 0.93 9.9 95/77 
Wong et al.
15
 246 
28.0 
 
M only 
F≥F2 0.41 0.84 
7.0 
 
79/76 
 
F≥F3 0.23 0.93 
8.7 
 
84/83 
 
F=4 0.10 0.95 
10.3 
 
92/88 
 
Wong et al.
16
 193 28.9 
Both probes used on each patient 
regardless of manufacturer’s 
recommendations. 
F≥F2 0.54 
M: 0.83 
 
 
 
XL: 0.80 
M: 7.0 
 
XL: 6.2 
 
79/64 
 
73/66 
 
F≥F3 0.33 
M: 0.87 
 
 
 
XL: 0.85 
M: 8.7 
 
XL: 7.2  
 
83/78 
 
78/78 
 
F=4 0.14 
M: 0.89 
 
M: 10.3 
 
81/83 
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XL: 0.91 
XL: 7.2 
 
92/70 
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Supplementary Figure 1. Receiver operating characteristic (ROC) curve of controlled attenuation 
parameter (CAP) for identifying (a) S≥S1, (b) S≥S2 and (c) S=S3.  
For each steatosis threshold, are overprinted: area under ROC curve (AUROC) with its 95% CI and the 
cut-off values maximizing Youden’s index, for a fixed sensitivity (Se) and Specificity (Sp) of 0.90.  
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Supplementary Figure 2. Receiver operating characteristic (ROC) curve of liver stiffness 
measurement (LSM) for identifying (a) F≥F2, (b) F≥F3 and (c) F=F4.  
For each fibrosis threshold, are overprinted: area under ROC curve (AUROC) with its 95% CI and the 
cut-off values maximizing Youden’s index, for a fixed sensitivity (Se) and Specificity (Sp) of 0.90. 
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Supplementary Figure 3. Impact of the prevalence on the liver stiffness measurement (LSM) cut-
offs computed taking into account the consequences of diagnostic error. 
This was undertaken (a) for the diagnostic of F≥F2 with a cost false positive (FP) 2 times, 5 times and 
10 times worse than a false negative (FN), (b) for the diagnostic of F=F4 with a cost FN 2 times, 5 
times and 10 times worse than a FP. The range of prevalence is 5 to 70% for F≥F2 and 0% to 10% for 
F=F4, respectively. For F≥F2, for a prevalence up to 20% the cut-offs value is 35.4 kPa. The cut-off 
value decreases from a prevalence of 20% for a cost for a FP 2 times worse than a FN, from a 
prevalence of 35% for a cost for a FP 5 times worse than a FN and from 55% for a cost for a FP 10 
times worse than a FN. For F=F4, for a prevalence up to 1% the cut-offs value is 35.7 kPa. The cut-off 
value decreases from a prevalence of 1% for a cost for a FN 10 times worse than a FP, from a 
prevalence of 5.5% for a cost for a FN 5 times worse than a FP and from 5.5% for a cost for a FN 10 
times worse than a FP.  
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